Giant-Cell Arteritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA, and Developments | AbbVie, Novartis, CSL, Kiniksa Pharma, Eli Lilly, Roche, Johnson & Johnson, MorphoSys

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Giant-Cell Arteritis pipeline constitutes 6+ key companies continuously working towards developing 6+ Giant-Cell Arteritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Giant-Cell Arteritis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Giant-Cell Arteritis Market.

The Giant-Cell Arteritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Giant-Cell Arteritis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Giant-Cell Arteritis treatment therapies with a considerable amount of success over the years.

*
Giant-Cell Arteritis companies working in the treatment market are AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others, are developing therapies for the Giant-Cell Arteritis treatment

*
Emerging Giant-Cell Arteritis therapies in the different phases of clinical trials are- Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others are expected to have a significant impact on the Giant-Cell Arteritis market in the coming years.

*
In June 2024, Johnson & Johnson has decided to discontinue a mid-stage trial evaluating its monoclonal antibody Tremfya (guselkumab) for the treatment of giant cell arteritis after it failed to meet the primary endpoint. As per a clinical update on clinicaltrials.gov, the Phase II THEIA study did not achieve the primary goal-the percentage of participants attaining glucocorticoid (GC)-free remission. Specific details regarding the results were not provided. However, the company reported "insufficient efficacy findings," which led to the decision to halt further support for the study, according to a J&J spokesperson's email to BioSpace. The spokesperson also mentioned that no new safety issues were identified.

*
In April 2024, AbbVie has announced favorable initial results from the first phase of the Phase III SELECT-GCA trial assessing upadacitinib (RINVOQ; 15mg, once daily) in combination with a tapered steroid regimen for adults diagnosed with giant cell arteritis (GCA).

Giant-Cell Arteritis Overview

Giant-Cell Arteritis (GCA), also known as temporal arteritis, is an inflammatory condition that affects the blood vessels, particularly the large and medium-sized arteries in the head, including the temporal arteries. It primarily affects older adults, typically over the age of 50. The inflammation can lead to symptoms such as severe headaches, scalp tenderness, vision problems, and jaw pain while chewing. If left untreated, GCA can lead to serious complications, including permanent vision loss. The condition is typically treated with corticosteroids to reduce inflammation and prevent complications.

Get a Free Sample PDF Report to know more about Giant-Cell Arteritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight [https://www.delveinsight.com/report-store/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Giant-Cell Arteritis Drugs Under Different Phases of Clinical Development Include:

*
Rinvoq(upadacitinib): AbbVie

*
Cosentyx (secukinumab): Novartis

*
KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals

*
Tremfya(guselkumab): Johnson & Johnson/ MorphoSys AG

*
Baricitinib: Eli Lilly and Company

*
Tocilizumab + Glucocorticoids (GCs): Roche Pharma

*
Secukinumab: Novartis

*
Guselkumab: Janssen Research & Development

*
Tocilizumab: Hoffmann-La Roche

*
adalimumab: Abbott

*
Upadacitinib: AbbVie

Giant-Cell Arteritis Route of Administration

Giant-Cell Arteritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Giant-Cell Arteritis Molecule Type

Giant-Cell Arteritis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Giant-Cell Arteritis Pipeline Therapeutics Assessment

*
Giant-Cell Arteritis Assessment by Product Type

*
Giant-Cell Arteritis By Stage and Product Type

*
Giant-Cell Arteritis Assessment by Route of Administration

*
Giant-Cell Arteritis By Stage and Route of Administration

*
Giant-Cell Arteritis Assessment by Molecule Type

*
Giant-Cell Arteritis by Stage and Molecule Type

DelveInsight's Giant-Cell Arteritis Report covers around 6+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Giant-Cell Arteritis product details are provided in the report. Download the Giant-Cell Arteritis pipeline report to learn more about the emerging Giant-Cell Arteritis therapies [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Giant-Cell Arteritis Therapeutics Market include:

Key companies developing therapies for Giant-Cell Arteritis are - Novartis, CSL, Kiniksa Pharmaceuticals, AbbVie, Johnson & Johnson, MorphoSys AG, and others.

Giant-Cell Arteritis Pipeline Analysis:

The Giant-Cell Arteritis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Giant-Cell Arteritis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Giant-Cell Arteritis Treatment.

*
Giant-Cell Arteritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Giant-Cell Arteritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Giant-Cell Arteritis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Giant-Cell Arteritis drugs and therapies [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Giant-Cell Arteritis Pipeline Market Strengths

*
Improved and clear treatment and diagnostic guidelines has led the patients and practitioners to clearly diagnose and treat the patients accurately.

*
While glucocorticoids remain the primary treatment, there is ongoing research into alternative and adjunctive therapies, such as biologic agents like tocilizumab. This diversification in treatment options provides more tailored approaches for patients, considering factors like side effects and individual response.

Giant-Cell Arteritis Pipeline Market Opportunities

*
The development of targeted biologic therapies offers a significant opportunity for improving treatment outcomes in GCA. Biologics, such as interleukin-6 (IL-6) inhibitors like tocilizumab, have shown promise in clinical trials. Further research and development in this area can lead to more effective and targeted treatments.

*
The introduction of biosimilars for existing therapies can increase competition, potentially reducing treatment costs and improving accessibility for patients.

Scope of Giant-Cell Arteritis Pipeline Drug Insight

*
Coverage: Global

*
Key Giant-Cell Arteritis Companies: AbbVie, Novartis, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, Eli Lilly and Company, Roche Pharma, Janssen Research & Development, Hoffmann-La Roche, Abbott, and others

*
Key Giant-Cell Arteritis Therapies: Rinvoq(upadacitinib), Cosentyx (secukinumab), KPL-301 (mavrilimumab), Tremfya(guselkumab), Baricitinib, Tocilizumab + Glucocorticoids (GCs), Guselkumab, Tocilizumab, adalimumab, Upadacitinib, and others

*
Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis current marketed and Giant-Cell Arteritis emerging therapies

*
Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers

Request for Sample PDF Report for Giant-Cell Arteritis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/giant-cell-arteritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Giant-Cell Arteritis Report Introduction

2. Giant-Cell Arteritis Executive Summary

3. Giant-Cell Arteritis Overview

4. Giant-Cell Arteritis- Analytical Perspective In-depth Commercial Assessment

5. Giant-Cell Arteritis Pipeline Therapeutics

6. Giant-Cell Arteritis Late Stage Products (Phase II/III)

7. Giant-Cell Arteritis Mid Stage Products (Phase II)

8. Giant-Cell Arteritis Early Stage Products (Phase I)

9. Giant-Cell Arteritis Preclinical Stage Products

10. Giant-Cell Arteritis Therapeutics Assessment

11. Giant-Cell Arteritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Giant-Cell Arteritis Key Companies

14. Giant-Cell Arteritis Key Products

15. Giant-Cell Arteritis Unmet Needs

16 . Giant-Cell Arteritis Market Drivers and Barriers

17. Giant-Cell Arteritis Future Perspectives and Conclusion

18. Giant-Cell Arteritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=giantcell-arteritis-pipeline-update-2024-fda-approvals-therapeutic-advancements-moa-roa-and-developments-abbvie-novartis-csl-kiniksa-pharma-eli-lilly-roche-johnson-johnson-morphosys]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.